{
    "hands_on_practices": [
        {
            "introduction": "The first crucial step in evaluating a proliferative breast lesion is determining if it shows atypia. This exercise focuses on the fundamental morphological distinction between usual ductal hyperplasia (UDH), a benign process, and atypical ductal hyperplasia (ADH), a clonal proliferation with increased cancer risk. By applying the concept of \"architectural rigidity,\" you will learn to connect the underlying biology of a lesion to its microscopic appearance, a core skill in diagnostic pathology .",
            "id": "4439751",
            "problem": "Atypical ductal hyperplasia (ADH) and usual ductal hyperplasia (UDH) both expand the epithelial compartment of terminal duct-lobular units (TDLUs), yet they arise from fundamentally different biological bases. UDH is a polyclonal reactive proliferation that retains heterogeneous cell phenotypes and lacks unified epithelial polarization. In contrast, ADH is a clonal neoplastic proliferation on the low-grade ductal intraepithelial neoplasia spectrum, sharing organizational principles with low-grade ductal carcinoma in situ (DCIS), including cohesive growth, apicobasal polarization, and formation of secondary lumina. These foundational differences manifest as distinct architecture. The concept of “architectural rigidity” refers to the degree to which the proliferating epithelium constructs consistently shaped and regularly spaced secondary spaces and bridges due to coordinated polarity and growth constraints.\n\nA core needle biopsy from a $48$-year-old patient with screening-detected microcalcifications shows several partially filled ducts on Hematoxylin and Eosin (H&E) staining. Three representative high-power fields are described:\n\nField $1$: Within a single enlarged duct cross-section, there are multiple evenly spaced, round, punched-out secondary lumina. The bridges between epithelial cell nests appear straight, and where they intersect, they do so at approximately right angles. The nuclei are relatively monotonous and show luminal-facing polarity around the secondary spaces. The pattern is repeated across the involved portion of the duct.\n\nField $2$: The duct is expanded by a mixture of cell types with variable cytoplasmic density. The epithelial cells show streaming and swirling, with overlapping nuclei and irregular, slit-like fenestrations that elongate along the long axis of the duct. Micropapillary projections are bulbous and vary in size and orientation, without consistent polarization toward any one luminal space.\n\nField $3$: There are epithelial bridges that branch at oblique angles, forming tear-drop and jagged fenestrations. The arrangement varies from one side of the duct to the other, and the intervening spaces show merging and remodeling with focal tufting.\n\nAssume immunohistochemistry is not available and that myoepithelial cells are present around all ducts. Using only the concept of architectural rigidity as derived from the biological bases above, which microscopic description most strongly supports a diagnosis of atypical ductal hyperplasia (ADH) rather than usual ductal hyperplasia (UDH) in a borderline lesion?\n\nA. Evenly spaced, round secondary lumina forming a rigid cribriform network with straight, perpendicular bridges and uniform luminal-facing nuclear polarization across the involved area.\n\nB. Heterogeneous epithelial proliferation with streaming, overlapping nuclei, irregular slit-like fenestrations that elongate along the duct axis, and variably bulbous micropapillae without consistent polarization.\n\nC. Continuous myoepithelial layer around the duct perimeter highlighted on H&E by a distinct basally located cell layer.\n\nD. Presence of necrosis and frequent mitotic figures within secondary lumina in a partially involved duct.",
            "solution": "### Step 1: Extract Givens\n\nThe problem provides the following definitions, observations, and constraints:\n\n*   **Atypical Ductal Hyperplasia (ADH)**: A clonal neoplastic proliferation on the low-grade ductal intraepithelial neoplasia spectrum. It shares organizational principles with low-grade ductal carcinoma in situ (DCIS), including cohesive growth, apicobasal polarization, and formation of secondary lumina.\n*   **Usual Ductal Hyperplasia (UDH)**: A polyclonal reactive proliferation that retains heterogeneous cell phenotypes and lacks unified epithelial polarization.\n*   **Architectural Rigidity**: A concept defined as \"the degree to which the proliferating epithelium constructs consistently shaped and regularly spaced secondary spaces and bridges due to coordinated polarity and growth constraints.\"\n*   **Clinical Data**: A core needle biopsy from a `$48$`-year-old patient with screening-detected microcalcifications. The sample shows several partially filled ducts on Hematoxylin and Eosin (H&E) staining.\n*   **Microscopic Field Descriptions**:\n    *   **Field $1$**: \"multiple evenly spaced, round, punched-out secondary lumina. The bridges between epithelial cell nests appear straight, and where they intersect, they do so at approximately right angles. The nuclei are relatively monotonous and show luminal-facing polarity around the secondary spaces. The pattern is repeated across the involved portion of the duct.\"\n    *   **Field $2$**: \"expanded by a mixture of cell types... epithelial cells show streaming and swirling, with overlapping nuclei and irregular, slit-like fenestrations... Micropapillary projections are bulbous and vary in size and orientation, without consistent polarization...\"\n    *   **Field $3$**: \"epithelial bridges that branch at oblique angles, forming tear-drop and jagged fenestrations. The arrangement varies from one side of the duct to the other... merging and remodeling with focal tufting.\"\n*   **Constraints**: Immunohistochemistry is not available. Myoepithelial cells are assumed to be present around all ducts.\n*   **Question**: Using the concept of architectural rigidity, identify the microscopic description that most strongly supports a diagnosis of ADH rather than UDH.\n\n### Step 2: Validate Using Extracted Givens\n\n1.  **Scientific Grounding**: The problem is firmly grounded in the principles of diagnostic breast pathology. The descriptions of ADH and UDH are pathologically accurate, reflecting the distinction between a clonal, neoplastic process (ADH) and a polyclonal, reactive process (UDH). The concept of \"architectural rigidity\" is a valid heuristic derived from the underlying biology: clonal proliferations (like ADH) are uniform and organized, while polyclonal ones (like UDH) are heterogeneous and disorganized. The microscopic descriptions accurately portray classic examples of these entities.\n2.  **Well-Posedness**: The problem is well-posed. It provides clear definitions and a specific conceptual tool (\"architectural rigidity\") to be applied to a set of observations to arrive at a single conclusion. The question is unambiguous and asks for the *best* fit among the choices, which is a standard task in differential diagnosis.\n3.  **Objectivity**: The language is objective and clinical. The descriptions are based on observable morphological features routinely assessed in pathology.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. It is a scientifically sound, well-posed, and objective problem in diagnostic histopathology. I will proceed with the solution.\n\n### Derivation\n\nThe core of the problem is to apply the concept of **architectural rigidity** to differentiate between Atypical Ductal Hyperplasia (ADH) and Usual Ductal Hyperplasia (UDH). The problem statement establishes a direct link between the biological origin of the lesion and its resulting architecture.\n\n1.  **ADH Biology and Architecture**: ADH is defined as a **clonal** proliferation. This means the proliferating cells are genetically identical or very similar, leading to uniform behavior. They exhibit **cohesive growth** and **apicobasal polarization**. This coordinated cellular activity results in a highly ordered structure. Following the problem's definition, this translates to high **architectural rigidity**. We would expect to see regular, repeating patterns, such as uniformly sized and spaced secondary lumina, and straight, organized bridges. The cells would be arranged in a predictable, non-random fashion.\n\n2.  **UDH Biology and Architecture**: UDH is defined as a **polyclonal** proliferation with **heterogeneous cell phenotypes**. This means multiple, distinct cell populations are growing together. It **lacks unified epithelial polarization**. This lack of coordination and inherent heterogeneity results in a disorganized, chaotic structure. This translates to low **architectural rigidity**. We would expect to see irregular spaces, haphazard cell streaming, overlapping nuclei, and a lack of consistent patterns. The architectural features would appear random and poorly formed.\n\nThe question asks which microscopic description most strongly supports a diagnosis of ADH. We must find the option that best describes high architectural rigidity, as derived from the clonal and polarized nature of ADH.\n\n### Option-by-Option Analysis\n\n**A. Evenly spaced, round secondary lumina forming a rigid cribriform network with straight, perpendicular bridges and uniform luminal-facing nuclear polarization across the involved area.**\nThis description is the epitome of high architectural rigidity.\n*   \"Evenly spaced, round secondary lumina\" and \"rigid cribriform network\" describe a highly ordered, geometric, and repeatable pattern. This is precisely what is expected from a clonal proliferation with coordinated growth constraints.\n*   \"Straight, perpendicular bridges\" (intersections at approximately `$90^\\circ$`) further emphasize this geometric regularity.\n*   \"Uniform luminal-facing nuclear polarization\" is a direct manifestation of the apicobasal polarization characteristic of ADH.\nThis description perfectly matches the architectural consequences of the biological basis of ADH. It is a more formal version of the description given for Field $1$.\n\n**Verdict:** **Correct**.\n\n**B. Heterogeneous epithelial proliferation with streaming, overlapping nuclei, irregular slit-like fenestrations that elongate along the duct axis, and variably bulbous micropapillae without consistent polarization.**\nThis description is a classic portrayal of low architectural rigidity.\n*   \"Heterogeneous epithelial proliferation\" points to the polyclonal nature of UDH.\n*   \"Streaming, overlapping nuclei\" and \"irregular slit-like fenestrations\" describe a disorganized, haphazard arrangement, directly contradicting the concept of rigidity.\n*   The lack of \"consistent polarization\" is a defining negative feature for ADH and a key characteristic of UDH.\nThis description strongly supports a diagnosis of UDH, not ADH. It is a formal summary of the features in Field $2$ and Field $3$.\n\n**Verdict:** **Incorrect**.\n\n**C. Continuous myoepithelial layer around the duct perimeter highlighted on H&E by a distinct basally located cell layer.**\nThe problem states to assume that \"myoepithelial cells are present around all ducts.\" The presence of an intact myoepithelial cell layer defines a proliferation as *in situ* (i.e., non-invasive). Both UDH and ADH are *in situ* proliferations. Therefore, this finding is required for a diagnosis of either entity and does not help distinguish between them. It only helps to rule out invasive carcinoma.\n\n**Verdict:** **Incorrect**.\n\n**D. Presence of necrosis and frequent mitotic figures within secondary lumina in a partially involved duct.**\nADH is part of the \"low-grade ductal intraepithelial neoplasia spectrum.\" While occasional mitoses can be seen, the presence of **necrosis** (specifically, central or comedo-type necrosis) and **frequent** mitotic figures are hallmarks of a higher-grade lesion, namely high-grade ductal carcinoma in situ (DCIS). These features indicate a more aggressive proliferation that has outgrown its blood supply. Finding them would argue against a diagnosis of ADH and in favor of DCIS.\n\n**Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Once a proliferative lesion is identified as having the architectural and cytologic features of low-grade ductal atypia, the next step is a quantitative assessment to determine its significance. This practice introduces the critical rule that separates atypical ductal hyperplasia (ADH) from low-grade ductal carcinoma in situ (DCIS) based on its size . Understanding and applying this evidence-based threshold is essential as it directly impacts patient diagnosis, risk stratification, and the course of clinical management.",
            "id": "4439776",
            "problem": "A breast core biopsy from a screening-detected microcalcification shows a monomorphic epithelial proliferation within several terminal duct-lobular units. The cells are evenly spaced, form rigid secondary lumina with cribriforming, and display low-grade cytologic atypia. A myoepithelial rim is intact around involved ducts, and there is no stromal invasion. You must decide whether the lesion should be classified as Atypical Ductal Hyperplasia (ADH) or Ductal Carcinoma In Situ (DCIS). \n\nUse the following fundamental base to reason your answer: \n- In surgical pathology, diagnostic categories are constructed to reflect biologic behavior, risk, and management. For intraductal epithelial proliferations, architectural and cytologic features are integrated with a quantitative assessment to separate lesions that share the morphology of low-grade DCIS but are limited in extent (ADH) from those meeting criteria for DCIS. \n- Quantitative thresholds are adopted to improve interobserver reproducibility and to align histologic categories with empiric observations about residual disease at excision and long-term risk. \n- The “greatest linear extent” is defined as the maximum contiguous span of unequivocal low-grade DCIS-like atypia measured in millimeters along a single slide (not area or number of foci), capturing the largest uninterrupted stretch of such morphology.\n\nWhich option best states the accepted greatest linear extent criterion distinguishing ADH from DCIS and correctly explains the historical and empirical basis for this cutoff?\n\nA. ADH is diagnosed when the greatest linear extent of unequivocal low-grade DCIS-like morphology is $< 2$ mm, and DCIS when it is $\\ge 2$ mm; this threshold was introduced in the era of widespread mammographic screening to standardize diagnoses, and is supported by studies showing that lesions $\\ge 2$ mm more often represent complete duct involvement and are associated with higher likelihood of residual disease at excision and management consistent with DCIS.\n\nB. ADH is diagnosed when the greatest linear extent is $< 3$ mm, and DCIS when it is $\\ge 3$ mm; the cutoff derives from molecular clonality studies demonstrating genomic instability above $3$ mm, which validated the threshold independent of morphology.\n\nC. ADH is diagnosed when fewer than $5$ ducts are fully involved, and DCIS when $> 5$ ducts are fully involved; the cutoff is based on consensus from the most recent international classification prioritizing duct counts over linear measurement to reduce measurement error.\n\nD. ADH and DCIS are separated by the presence of comedo-type necrosis rather than extent; the $2$ mm threshold was introduced for billing simplification and lacks empirical correlation with risk or residual disease.\n\nE. ADH is diagnosed when the greatest linear extent is $< 2$ cm, and DCIS when it is $\\ge 2$ cm; this large-size cutoff was adopted to avoid overdiagnosis of DCIS in small core biopsies and has been validated by upgrade rates on excision.",
            "solution": "The user has provided a problem from the field of surgical pathology, specifically concerning the diagnostic criteria for proliferative breast lesions. The task is to validate the problem statement and, if valid, determine the correct diagnostic criterion and its basis from the given options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Clinical Context**: Breast core biopsy for screening-detected microcalcification.\n*   **Histologic Findings**:\n    *   Monomorphic epithelial proliferation within several terminal duct-lobular units (TDLUs).\n    *   Architecture: Evenly spaced cells, rigid secondary lumina, cribriforming.\n    *   Cytology: Low-grade atypia.\n    *   Myoepithelial layer: Intact around involved ducts.\n    *   Invasion: No stromal invasion.\n*   **Diagnostic Question**: Is the lesion Atypical Ductal Hyperplasia (ADH) or Ductal Carcinoma In Situ (DCIS)?\n*   **Provided Principles (Fundamental Base)**:\n    1.  Diagnostic categories are based on biologic behavior, risk, and management.\n    2.  For intraductal proliferations, architectural and cytologic features are combined with a **quantitative assessment**.\n    3.  This quantitative assessment separates **ADH** (lesions with low-grade DCIS morphology but limited extent) from **DCIS**.\n    4.  Quantitative thresholds enhance interobserver reproducibility and align diagnosis with empirical data on residual disease and long-term risk.\n    5.  The key metric is the **“greatest linear extent”**: the maximum contiguous span of unequivocal low-grade DCIS-like atypia on a single slide, measured in millimeters. This is not an area or a count of foci.\n\n**Step 2: Validate Using Extracted Givens**\n\n*   **Scientifically Grounded (Critical)**: The problem is firmly grounded in the established principles of breast pathology. The described histologic features (monomorphic proliferation, cribriforming, low-grade atypia) are characteristic of a spectrum of lesions that includes ADH and low-grade DCIS. The concept of distinguishing these entities based on a quantitative extent criterion is the cornerstone of modern breast pathology practice, as codified by the World Health Organization (WHO) and other pathology consensus groups. The provided principles accurately reflect the rationale behind these diagnostic rules.\n*   **Well-Posed**: The problem is well-posed. It presents a clear and classic diagnostic dilemma and asks for the specific, accepted criterion used to resolve it, along with the empirical basis for that criterion. A single, correct answer based on established medical guidelines exists.\n*   **Objective (Critical)**: The language is precise, objective, and uses standard medical terminology. The question asks for the \"accepted\" criterion, which refers to a verifiable standard within the field, not a subjective opinion.\n\nThe problem does not exhibit any flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity. The provided scenario and principles are an accurate and self-contained representation of the diagnostic challenge.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. The solution process will now proceed.\n\n### Solution Derivation\n\nThe problem requires identifying the criterion that separates Atypical Ductal Hyperplasia (ADH) from low-grade Ductal Carcinoma In Situ (DCIS) when the cytomorphological and architectural features are identical to those of low-grade DCIS.\n\nThe \"Fundamental Base\" provided correctly states that this distinction is primarily quantitative and relies on measuring the \"greatest linear extent\" of the proliferation. The historical context for this rule is the rise of mammographic screening, which led to the frequent biopsy of small, non-palpable lesions, creating a diagnostic \"grey zone\" between florid usual ductal hyperplasia and well-developed DCIS. To standardize diagnosis and management for these borderline lesions, a size-based criterion was adopted.\n\nThe specific, widely accepted criterion is based on a linear measurement cutoff of $2$ millimeters.\n*   A proliferative lesion with the cytologic and architectural features of low-grade DCIS that has a greatest linear extent of less than $2$ mm is classified as ADH.\n*   If the exact same proliferation has a greatest linear extent of $2$ mm or greater, it is classified as low-grade DCIS.\n\nThe empirical basis for this $2$ mm threshold is derived from clinical outcome studies. These studies have demonstrated that lesions fulfilling the morphologic criteria for low-grade DCIS but measuring less than $2$ mm have a lower risk of being associated with more extensive DCIS or invasive carcinoma upon subsequent surgical excision (\"upgrade rate\"). Conversely, lesions measuring $2$ mm or more have a significantly higher risk of upgrade, justifying management as carcinoma in situ (i.e., surgical excision aiming for negative margins). This threshold, therefore, serves as a pragmatic and risk-stratifying tool that guides clinical management.\n\nWe will now evaluate each option against this established standard.\n\n### Option-by-Option Analysis\n\n**A. ADH is diagnosed when the greatest linear extent of unequivocal low-grade DCIS-like morphology is $< 2$ mm, and DCIS when it is $\\ge 2$ mm; this threshold was introduced in the era of widespread mammographic screening to standardize diagnoses, and is supported by studies showing that lesions $\\ge 2$ mm more often represent complete duct involvement and are associated with higher likelihood of residual disease at excision and management consistent with DCIS.**\n\n*   **Criterion**: The statement of the criterion (ADH $< 2$ mm, DCIS $\\ge 2$ mm) is correct. This is the standard quantitative threshold used in practice and endorsed by the WHO.\n*   **Basis**: The explanation of the historical context (era of mammographic screening) and the empirical basis (correlation with risk of residual disease/upgrade at excision) is entirely accurate. The $2$ mm cutoff is a risk-stratification tool grounded in clinical data.\n*   **Verdict**: **Correct**.\n\n**B. ADH is diagnosed when the greatest linear extent is $< 3$ mm, and DCIS when it is $\\ge 3$ mm; the cutoff derives from molecular clonality studies demonstrating genomic instability above $3$ mm, which validated the threshold independent of morphology.**\n\n*   **Criterion**: The stated threshold of $3$ mm is incorrect. The accepted international standard is $2$ mm.\n*   **Basis**: While both ADH and DCIS are clonal proliferations with genetic alterations, the specific $2$ mm clinical rule was not derived primarily from a discrete molecular threshold at $3$ mm. The basis is clinicopathologic correlation, not a direct molecular assay cutoff.\n*   **Verdict**: **Incorrect**.\n\n**C. ADH is diagnosed when fewer than $5$ ducts are fully involved, and DCIS when $> 5$ ducts are fully involved; the cutoff is based on consensus from the most recent international classification prioritizing duct counts over linear measurement to reduce measurement error.**\n\n*   **Criterion**: This presents a criterion based on counting involved ducts. While historical criteria involved concepts like the involvement of \"two duct spaces,\" the modern and more reproducible standard is linear extent measurement. The \"Fundamental Base\" provided in the problem explicitly defines the metric as \"greatest linear extent\" and not duct counting.\n*   **Basis**: The claim that recent classifications prioritize duct counts over linear measurement is false. The current WHO classification prioritizes the $2$ mm linear extent rule for its superior interobserver reproducibility.\n*   **Verdict**: **Incorrect**.\n\n**D. ADH and DCIS are separated by the presence of comedo-type necrosis rather than extent; the $2$ mm threshold was introduced for billing simplification and lacks empirical correlation with risk or residual disease.**\n\n*   **Criterion**: The presence of comedo-type necrosis is sufficient to diagnose DCIS (specifically, high-grade DCIS) regardless of its extent. However, its *absence* is what defines the low-grade lesions where the ADH vs. DCIS distinction must be made based on extent. The statement is a misleading oversimplification.\n*   **Basis**: The assertion that the $2$ mm threshold is for \"billing simplification\" and \"lacks empirical correlation with risk\" is factually wrong and contradicts the very reason for its existence. The threshold is fundamentally an evidence-based, risk-stratifying guideline.\n*   **Verdict**: **Incorrect**.\n\n**E. ADH is diagnosed when the greatest linear extent is $< 2$ cm, and DCIS when it is $\\ge 2$ cm; this large-size cutoff was adopted to avoid overdiagnosis of DCIS in small core biopsies and has been validated by upgrade rates on excision.**\n\n*   **Criterion**: The unit is incorrect. A cutoff of $2$ cm ($20$ mm) is an order of magnitude too large. A $2$ cm intraductal proliferation is a substantial DCIS, not a borderline lesion. The correct unit is millimeters (mm).\n*   **Basis**: The rationale is nonsensical given the incorrect unit. This would misclassify vast numbers of small DCIS lesions as ADH.\n*   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "A diagnosis of ADH on a core needle biopsy is a statement about a small sample, not the entire lesion. This final practice moves from pure diagnosis to clinical risk assessment by exploring the concept of the \"upgrade rate\"—the probability that a more serious lesion, like DCIS, will be found upon surgical excision. Using the principles of Bayesian reasoning with a hypothetical dataset, you will calculate this risk, demonstrating how pathologists use statistical tools to guide clinical decision-making and patient counseling .",
            "id": "4439726",
            "problem": "A 54-year-old patient undergoes stereotactic core biopsy for grouped microcalcifications. Based on imaging features alone, a multidisciplinary conference estimates the pretest probability that the targeted lesion would prove to be ductal carcinoma in situ (DCIS) at surgical excision as $0.25$. The core biopsy is interpreted as atypical ductal hyperplasia (ADH). Treat the core interpretation as a binary diagnostic test with the following properties, validated against the gold standard of surgical excision:\n- Sensitivity for DCIS defined as $P(\\text{ADH on core} \\mid \\text{DCIS present at excision}) = 0.40$.\n- False positive rate defined as $P(\\text{ADH on core} \\mid \\text{no DCIS at excision}) = 0.10$.\n\nAssume the pretest probability is the prior probability $P(\\text{DCIS})$ for this lesion and that the test characteristics apply to the same target population. Using Bayes’ theorem and the core definitions of sensitivity, specificity, and prior probability, calculate the posterior probability $P(\\text{DCIS} \\mid \\text{ADH on core})$. Express your final answer as a decimal rounded to four significant figures. No percent sign is allowed.",
            "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\nThe verbatim data provided in the problem statement are as follows:\n- Pretest probability of ductal carcinoma in situ (DCIS): $0.25$.\n- Core biopsy interpretation: Atypical ductal hyperplasia (ADH).\n- Sensitivity for DCIS: $P(\\text{ADH on core} \\mid \\text{DCIS present at excision}) = 0.40$.\n- False positive rate: $P(\\text{ADH on core} \\mid \\text{no DCIS at excision}) = 0.10$.\n- Task: Calculate the posterior probability $P(\\text{DCIS} \\mid \\text{ADH on core})$ and express it as a decimal rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria.\n- **Scientifically Grounded**: The problem is well-grounded in the principles of medical statistics and Bayesian probability theory. The clinical scenario described (stereotactic biopsy for microcalcifications, finding ADH, and assessing the risk of underlying DCIS) is a standard and realistic situation in breast pathology and radiology. The concepts of pretest probability (prior), sensitivity, false positive rate, and posterior probability are fundamental to diagnostic test evaluation. The numerical values provided are plausible for this clinical context.\n- **Well-Posed**: The problem is well-posed. It provides all the necessary information to calculate the desired posterior probability using Bayes' theorem. A unique and stable solution exists.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language. There are no subjective or opinion-based elements.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, well-posed, objective, and free from any of the specified flaws. The solution process may proceed.\n\n### Solution Derivation\nThe objective is to calculate the posterior probability of a patient having ductal carcinoma in situ (DCIS) at surgical excision, given that a preceding core biopsy yielded a diagnosis of atypical ductal hyperplasia (ADH). This calculation is a direct application of Bayes' theorem.\n\nLet us define the following events:\n- $D$: The event that DCIS is present at surgical excision.\n- $\\neg D$: The event that DCIS is not present at surgical excision (the complementary event to $D$).\n- $A$: The event that the core biopsy is interpreted as ADH.\n\nFrom the problem statement, we are given the following probabilities:\n1.  The prior probability of DCIS, $P(D)$, which is the pretest probability:\n    $$P(D) = 0.25$$\n2.  The sensitivity of the ADH finding for DCIS, which is the conditional probability of finding ADH on the core biopsy given that DCIS is truly present:\n    $$P(A \\mid D) = 0.40$$\n3.  The false positive rate of the ADH finding, which is the conditional probability of finding ADH on the core biopsy given that DCIS is not present:\n    $$P(A \\mid \\neg D) = 0.10$$\n\nThe quantity to be calculated is the posterior probability of DCIS given the ADH finding on the core biopsy, denoted as $P(D \\mid A)$.\n\nBayes' theorem states:\n$$P(D \\mid A) = \\frac{P(A \\mid D) P(D)}{P(A)}$$\n\nThe denominator, $P(A)$, is the total probability of observing an ADH result. It can be calculated using the law of total probability, marginalizing over the a priori possibilities (presence or absence of DCIS):\n$$P(A) = P(A \\mid D) P(D) + P(A \\mid \\neg D) P(\\neg D)$$\n\nTo use this formula, we first need to determine $P(\\neg D)$. Since $D$ and $\\neg D$ are complementary events, their probabilities sum to $1$:\n$$P(\\neg D) = 1 - P(D) = 1 - 0.25 = 0.75$$\n\nNow, we can substitute the known values into the expression for $P(A)$:\n$$P(A) = (0.40)(0.25) + (0.10)(0.75)$$\n$$P(A) = 0.100 + 0.075$$\n$$P(A) = 0.175$$\n\nWith the total probability of observing ADH calculated, we can now compute the posterior probability $P(D \\mid A)$ by substituting all values into Bayes' theorem:\n$$P(D \\mid A) = \\frac{P(A \\mid D) P(D)}{P(A)} = \\frac{(0.40)(0.25)}{0.175}$$\nThe numerator is a component we already calculated for $P(A)$:\n$$P(D \\mid A) = \\frac{0.100}{0.175}$$\n\nTo simplify the fraction:\n$$P(D \\mid A) = \\frac{100}{175} = \\frac{4 \\times 25}{7 \\times 25} = \\frac{4}{7}$$\n\nThe problem requires the answer to be expressed as a decimal rounded to four significant figures. We perform the division:\n$$\\frac{4}{7} \\approx 0.57142857...$$\nRounding this value to four significant figures yields $0.5714$.\n\nThus, the posterior probability that the lesion is DCIS, given that the core biopsy showed ADH, is $0.5714$.",
            "answer": "$$\\boxed{0.5714}$$"
        }
    ]
}